INTRODUCTION
Adenoviruses (Ads) contain more than 20 genes dedicated to control various aspects of the innate or acquired immune responses of the infected host. Some of these functions are not necessary for the successful replication of the virus in cultured cells; however, they appear to target processes that are essential for the survival of virus during acute or latent infection in vivo (reviewed in Lukashok and Horwitz, 1997; Shenk, 1996; Wold et al., 1999) . Many of these immunoregulatory genes are clustered in early region 3 (E3), which contains NF-B-binding sites in the E3 promoter (Deryckere and Burgert, 1996) . Proteins encoded in the E3 region can inhibit peptide presentation by class I MHC and cell death by TNF␣-, Fas-, or TRAIL-induced mechanisms of cytolysis (Wold et al., 1999) . Since the activity of the NF-B transcription factor is enhanced after stimulation of the TNF␣ signal transduction pathway, the E3 genes should be activated during the inflammatory response.
The focus of this minireview is on two areas of research: (1) A progress report on the nature and function of the cell proteins that interact with one of the Ad E3 proteins (14.7K), an inhibitor of TNF␣-induced cytolysis; and (2) the use of the immunoregulatory Ad E3 genes in murine models in vivo to reduce the immune responses to allogeneic islet transplantation and to prevent islet destruction during the autoimmune response that results in type I or insulin-dependent diabetes mellitus (IDDM). There are excellent recent reviews about other aspects of the E3 proteins and other adenoviral proteins that regulate the interferon response, cell death, and the cell cycle (Mahr and Gooding, 1999; Wold et al., 1999) .
Because viruses have evolved as intracellular parasites over millions of years, they have finely tuned the process of acquiring molecules and targeting pathways to deal with counterattacking host immune responses.
Using the techniques of modern molecular biology and genetics, we have attempted to find the host molecules targeted by the Ad E3-14.7K viral immunoregulatory protein. In most cases, the host molecules that we identified were novel and involved signaling pathways that had not been sufficiently elucidated to easily explain the function of the Ad E3-14.7K protein. However, as we and others have contributed to an understanding of these signal transduction pathways, exciting new observations are being made. Before the advent of modern cloning techniques, viruses were critical reagents for discovering and understanding essential cellular processes such as mRNA splicing (Berget et al., 1977) , oncogene function (van der Eb et al., 1977) , and eukaryotic DNA replication (Challberg and Kelly, 1979; Friefeld et al., 1984) . I believe that we have returned in part to such an era of discovery for the study of viral immunoregulatory genes. By determining cell molecules which are the targets of proteins such as Ad E3-14.7K, viruses can help us bring together the vast amount of knowledge that has been produced by immunologists and cell and molecular biologists into coherent immunoregulatory pathways. These pathways, which control inflammatory responses, can then be used therapeutically to control disease processes. In some cases, the complete mechanistic understanding of the signaling pathways targeted by viral proteins will have to wait for additional data from other areas of biology; however, in the interim it will still be possible to use the viral immunoregulatory proteins in therapeutic or prophylactic ways to alter disease processes. This minireview will attempt to focus on the results as well as the processes by which we have pursued these goals of discovery.
DESCRIPTION OF THE ADENOVIRUS E3
IMMUNOREGULATORY PROTEINS
Ad E3-gp19K
An Ad E3-19kDa glycoprotein (gp19K) retains the class I major histocompatibility complex (MHC) heavy chain in the endoplasmic reticulum (ER) (Burgert and Kvist, 1985) and also prevents tapasin processing of peptides that bind to the class I MHC molecule (Bennett et al., 1999) . The gp19K contains a lysine KKXX (X ϭ any amino acid) motif at its carboxyl end, and this serves to retrieve proteins from the Golgi back to the ER (Jackson et al., 1993 ) (see Fig. 1 for transcription and translation map of genes encoded in the E3 region).
Ad E3-14.7K
An Ad E3-14.7kDa protein (14.7K) inhibits apoptosis induced by TNF␣ by mechanisms which have not been fully elucidated; however, 14.7K does not appear to affect the amounts or distribution of the TNF␣ receptor. 14.7K inhibits the synthesis of arachidonic acid induced by TNF␣, a process which could have effects on apoptosis or the pathway affecting the inflammatory response (Krajcsi et al., 1996) . There is also one report that 14.7K from Ad type 5 can bind to caspase 8 and inhibit Fasinduced apoptosis ; however, we have failed to confirm these interesting observations using the related protein from Ad2. Our studies on the mechanism of action of the 14.7K protein will be one of the topics discussed in this review.
Ad E3-10.4K/14.5K complex (RID␣/␤) A heterotrimer of Ad E3-10.4kDa (10.4K) and Ad E3-14.5kDa (14.5K) polypeptides also inhibits TNF␣ and Fas ligand-induced cell death by internalizing their receptors and promoting their degradation in lysosomes (Elsing and Burgert, 1998; Shisler et al., 1997; Tollefson et al., 1998) . The 10.4K and 14.5K proteins have been renamed RID␣ and RID␤, respectively, to highlight their function as mediators of receptor internalization and degradation, which occur in the lysosomes (Wold et al., 1999) .
Ad E3-11.6K (ADP)
All of the E3 proteins described above prevent cell killing by various mechanisms that either use soluble ligands such as TNF␣ or cell-mediated mechanisms of cell killing such as by cytotoxic T lymphocytes (CTL). In contrast to the antiapoptotic proteins coded in the E3 region, there is an 11.6-kDa E3 (11.6K) protein, which can induce cell death . It has been renamed ADP (adenovirus death protein) and its synthesis appears to be regulated differently than all the others from the early region 3 promoter. ADP is primarily expressed late in the virus infectious cycle using an mRNA not shown in Fig. 1 , presumably initiating from the strong major late promoter that also upregulates the synthesis of the structural proteins needed in large amounts to make progeny virus. ADP also has been recognized as a facilitator of exit of assembled virus from the nucleus. In the absence of ADP the amounts of normal virus made have difficulties in exiting the cell resulting in smaller plaque size. Adenovirus vectors engineered to overex-FIG. 1. Map of the E3 region. The proteins, whose genes are encoded in the E3 region, are shown as rectangles juxtaposed to the family of spliced mRNAs (arrows) that direct their synthesis. The Ad E3 gp19K, 11.6K (ADP), 10.4K/14.5K (RID␣‫,)␤گ‬ and 14.7K, for which some functions are known, are shown as solid rectangles and are discussed further in the text. Although some of the other open reading frames (ORFs), shown as hatched rectangles, have been shown to code for proteins, their functions have not been elucidated (Wold et al., 1995) . The E3 promoter is at the left and is transactivated during Ad infection by the Ad E1A protein; however, in the Ad E3 transgenic animals, the rat insulin promoter is placed upstream of this transcription region. There are two polyadenylation sites (pA) used by various members of the E3 mRNA family. press ADP and be selectively toxic to tumor cells have been studied as potentially therapeutic agents for killing malignant cells (Doronin et al., 2000) .
OTHER ADENOVIRUS IMMUNOREGULATORY PROTEINS AND VA RNA1
There are other Ad proteins coded by genes in the E1B region that inhibit apoptosis. The E1B-19kDa (19K) is a homologue of Bcl-2 and binds to proapoptotic members of this family of proteins residing in mitochondrial membranes (reviewed in Chinnadurai, 1998; White, 1998) . The E1B-19K inhibits release of both Apaf-1 and cytochrome c following p53 signaling, which prevents Apaf-l and cytochrome c from binding to procaspase 9 and activating mechanisms of apoptosis. The E1B-19K can also act through upstream signals requiring the interactions of death domain (DD)-containing proteins with the intracellular domains of receptors of death signals (Perez and White, 1998) . Some of the molecules on these pathways will be described further below (Fig. 2 ). Another E1B protein (E1B-55kDa) binds directly to p53 and prevents its activation of transcription of proapoptotic proteins (Martin and Berk, 1998) . Ads have also evolved the ability to prevent interferon-induced inhibition of protein synthesis and this function resides in a "viral-associated RNA" (VA RNA1) itself, which can bind to and inhibit the dsRNA-dependent protein kinase (PKR) phosphorylation of EIF2␣ (Mathews and Shenk, 1991) . Phosphorylation of this site ordinarily inhibits the initiation of protein synthesis; however, VA RNA permits viral protein synthesis to continue in the presence of interferons. There are also inhibitory effects of the E1A proteins on the activity of type I interferons and interferon ␥ in the induction of antiviral genes (Leonard and Sen, 1997) . Control of class I MHC, TNF, or Fas-ligand cytolysis and inhibition of interferons are targets shared by a variety of viruses, but the exact step targeted on the each of these pathways often varies between viruses.
Implications of immunoregulatory proteins in the virus life cycle
All of these immunoregulatory functions presumably facilitate the survival of adenoviruses as intracellular pathogens; however, the absence of a good animal model for studying human adenovirus pathogenesis has left these conclusions somewhat tentative (Lukashok and Horwitz, 1998) . Human adenoviruses can enter murine cells and express early viral genes as well as gene products controlled by exogenous promoters such as those introduced in Ads used as gene therapy vectors; however, human Ads do not complete their replication cycle in murine cells in vivo or in vitro (Ginsberg et al., 1991) . Ad gene therapy vectors are usually deleted of E3 genes to increase the potential packaging size of the foreign gene; however, a variety of Ad vectors have been designed to contain all or parts of the E3 region in attempts to decrease the immune response to the virus and prolong the expression of the therapeutic gene (Bruder et al., 1997; Ilan et al., 1997; Poller et al., 1996) . Ads with various mutations especially in the E3 region have been studied for altered virulence and pathogenicity in murine models (Ginsberg and Prince, 1994; Sparer et al., 1996) . Changes in the inflammatory response following deletions of individual E3 genes have been demonstrated. Other studies used mice expressing the Ad E3-14.7K as a transgene under the control of the lungspecific surfactant C promoter (Harrod et al., 1998) . Such mice, which were infected with Ad E3 deletion mutants, developed less of an inflammatory response than nontransgenic littermates because of the presence of the 14.7K as a transgene.
CELL PROTEINS THAT INTERACT WITH THE AD E3-14.7K
In an attempt to learn more about the molecular mechanism of inhibition of apoptosis by the Ad E3-14.7K protein, it was used as bait in the yeast two-hybrid system to determine its intracellular interacting targets. Initially, four 14.7K-interacting proteins (FIPs) were identified by this procedure, and three have been characterized ( Fig.  3) (Li et al., , 1998 (Li et al., , 1999 . The interactions of each of the three FIPs with the Ad E3-14.7K protein were confirmed within mammalian cells (293 HEK) and by in vitro FIG. 2 . TNF and Fas signal transduction pathway. The important molecules on the signal transduction pathway that lead to either cell death or activation of NF-B, an antiapoptotic signal, are shown. The controls that drive the pathway toward apoptosis or prevention of cell death are not completely understood. The TNF receptor and Fas are shown on the cell surface and the first molecules, TRADD and FADD, to which they bind are indicated. The interactions of FIP-3 (NEMO‫گ‬IKK␥) with the "upstream" molecule RIP and the "downstream" molecules such as IKK␣‫گ‬IKK␤ are indicated. The latter complex of kinases phosphorylate IB␣ promoting its ubiquination and degradation. This frees NF-B from its cytoplasmic tether (IB␣) to move into the nucleus and increase transcription from NF-B-responsive sequences. Ad E3-14.7K, which binds to FIP-3 and may also bind to caspase 8, reverses the proapoptotic effect of FIP-3 after transfection. assays. The three FIPs were each novel proteins, when first isolated 5 years ago at the outset of these experiments. However, other investigators involved with the elucidation of specific pathways, such as the signal transduction pathway affecting NF-B, have come upon each of the FIPs independently using totally different approaches. The following summary of the properties and functions of the FIPs should be considered a progress report as many aspects of their function during adenovirus infection or in normal uninfected cells have still not been elucidated.
FIP-3 (NEMO or IKK␥)
FIP-3 has been the most intensively studied in our laboratory and by others interested in the NF-B pathway of signal transduction. FIP-3 causes a readily apparent morphologic abnormality after transient transfection of a variety of cells, which then proceed to apoptosis (Li et al., 1999) . Cell death is delayed and less profound than that produced by a variety of overexpressed proteins on the death pathway, such as the TNF receptor (TNF-R). Apoptosis by FIP-3 is reversed by 70% in the presence of Ad E3-14.7K, suggesting that FIP-3 may be one of the important targets for the inhibition of cell death by Ad E3-14.7K. We also demonstrated that FIP-3 interacted with RIP (receptor-interacting protein), IKK␤ (inhibitor of kappa kinase beta), and NIK (NF-B-inducing kinase) (Li et al., 1999) . These proteins appear to have various key roles in signaling from TNF-R, through the phosphorylation, ubiquitination, and degradation of IB␣ to activate NF-B, which is a well-studied inhibitor of cell death induced by TNF␣ (Beg and Baltimore, 1996; Van Antwerp et al., 1996) . Although it has been shown convincingly that FIP-3 is an essential component for the activation of NF-B, overexpression of FIP-3 by transient transfection clearly inhibits NF-B reporter plasmids (Li et al., 1999; Rothwarf et al., 1998; Wang et al., 1988; Yamaoka et al., 1998; Zhang et al., 2000) . The essential nature of FIP-3 was first demonstrated by complementation assays in fibroblasts NEMO (NF-B essential modulator), the mouse homologue of FIP-3, was isolated by its ability to complement the deficiency in NF-B activity in a mutant fibroblast cell line (Yamaoka et al., 1998) . Another report described the isolation of a molecule called IKK␥, which was associated with IKK␤ in a high-molecular-weight complex and enhanced the kinase activity of IKK␤; however, IKK␥ had no intrinsic protein kinase activity when assayed alone (Rothwarf et al., 1998) . IKK␥ is identical to FIP-3. It is intriguing that observations on the domain structure of FIP-3 have shown that the IKK␤-interacting domain, which should activate NF-B by destruction of the IB␣ molecule retaining NF-B in the cytoplasm, is separable from the domain that inhibits the activity of NF-B after transfection (Ye et al., 2000) . The observations of low levels of FIP-3‫گ‬NEMO‫گ‬IKK␥ being required for NF-B activation and higher amounts being inhibitory have suggested that this molecule may be a molecular switch for fine regulation of the activity of NF-B. Although the levels of FIP-3 transcripts in various organs are quite different, the levels of FIP-3 have not been shown to be modulated by TNF␣ or any signal transduction modulator studied thus far (Li et al., 1999) . A recent report using short peptides representing sequences of IKK␤ that interact with FIP-3‫گ‬NEMO‫گ‬IKK␥ has shown that one peptide inhibits the interaction of these two proteins, preventing induction of NF-B but not its basal activity. When the inhibitory peptide was modified to promote its entry into cells in vivo, the peptide also decreased the inflammatory response following two separate noxious stimuli (May et al., 2000) . These studies indicate that it may be possible to design inhibitors of the NF-B signaling pathway that will inhibit NF-B following inflammatory stimuli but not interfere with the basal level of expression, which appears necessary for cell survival.
FIP-2 (NRP)
FIP-2 has domains of homology with FIP-3 and has also been called NEMO-related protein (NRP), but does not share any of the functions of the NF-B regulatory protein (Li et al., 1998; Schwamborn et al., 2000) . FIP-2 also does not cause cell death when overexpressed following transfection protocols. However, if the apoptotic effects of expressing the TNF-R or RIP are inhibited by Ad E3-14.7K, the addition of FIP-2 causes apoptosis. Although there has not been a cellular homologue of Ad E3-14.7K recognized, we have postulated that one may exist and subsequently be controlled by altering the amounts of FIP-2. FIP-2 has been shown to be transcriptionally regulated by the addition of TNF␣. A potentially important function for FIP-2 has been suggested by the demonstration that FIP-2 binds to the polyglutamine tracts in abnormal huntingtin protein, the putative pathogenic molecule identified as the product of the mutated gene in Huntington's chorea (Faber et al., 1998) . Abnormal huntingtin protein is the product of expansion of the trinucleotide repeat that results in polyglutamine tracts that appear to be associated with apoptosis in cells of neuronal origin. The function of FIP-2 and/or Ad E3-14.7K in preventing cell death induced by huntingtin protein is currently being investigated.
FIP-1 (Rag-A), GIP-1 (TCTEL), and GIP-2 FIP-1 is a small GTPase isolated in our laboratory also by using Ad E3-14.7K as bait. FIP-1 is identical to RAG-A (Schurmann et al., 1995) , a molecule isolated by probing with sequences common to a variety of GTPases. FIP-1 does not cause cell death but was shown to bind to a variety of phosphorylated proteins upon stimulation with TNF␣ . Because we anticipated that FIP-1 may require other proteins to learn about its function, we used it as bait in the yeast two-hybrid system and isolated two new interesting cell proteins. The first is a component we initially called GIP-1 (GTPase-interacting protein); however, it is identical to TCTEL, a 14-kDa component of the microtubule motor protein dynein (Campbell et al., 1998; Lukashok et al., 2000) . In the presence of the bridging protein FIP-1, a ternary complex can form between Ad E3-14.7K and TCTEL. FIP-1 can bind to each of the other two components separately. We have been searching for the functional significance of an early Ad protein binding to a component of the microtubule motor dynein. Microtubules have been shown to be important in the transport of the adenovirus particle from the endocytic vesicle across the cytoplasm to the nucleus during the process of viral entry (Luftig and Weihing, 1975) . However, Ad E3-14.7K is not believed to be a structural component of the virion, as it is only made after the viral DNA has entered the nucleus and been transcribed to make the early viral proteins. We are currently conducting experiments in vitro to determine if Ad E3-14.7K can affect the function of dynein in moving the virus toward the minus (nuclear membrane) end of the microtubules. It is also possible that the Ad E3-14.7K protein could affect exit of the virus from the nucleus after new progeny virus is made. As described above, the Ad E3-11.6K protein has been shown to be involved in exit of the virus from the nucleus . Perhaps the 14.7K protein might facilitate the transport of viral particles in the cytoplasm from the vicinity of the nucleus to the plasma membrane along microtubules in a mirror image process to that involved in viral entry; however, this is a speculation that awaits experimental verification as little is known about the mechanism of adenovirus exit from the cell.
A second protein that we discovered using FIP-1 (RagA) as bait in the yeast two-hybrid system was another small GTPase that we named GIP-2 (Accession no. AF323609; Lukashok, S. A., Buntzman, A. S., Ye, J. and Horwitz, M. S., personal observations). GIP-2 has structural similarities to the Saccharomyces cerevisiae Gtr2, and FIP-1 has structural similarities to the yeast Gtr1 . FIP-1 and GIP-2 differ from other small GTPases but are sufficiently similar to each other to be classified as a new GTPase family in a dendrogram analysis of small GTPases. Loss of function (lof) mutations either in Gtr1 or Gtr2 reversed the temperaturedependent growth defect of mutations in RCC1, a protein that has been shown to be important in the formation of the centrosomes of the mitotic spindle as well as in nuclear-cytoplasm transport of macromolecules (Hirose et al., 1998 . In addition, the mRNA of the mouse homologue of human GIP-2 appears to be over-expressed in metastatic cells (Nakaji et al., 1999) . The effects of Ad E3-14.7K on the function of GIP-2 in these processes have not yet been investigated. Thus, there is a fertile area for further investigation to determine whether the adenovirus protein can affect microtuble-based processes such as centrosome function and metastases.
ADENOVIRUS E3 PROTEINS FACILITATE ALLOGENEIC ISLET SURVIVAL AFTER TRANSPLANTATION AND PREVENT AUTOIMMUNE DIABETES IN MURINE MODELS

Allogeneic transplantation of islets
We postulated that the Ad immunoregulatory genes could be used therapeutically or prophylactically under other conditions for which the goals of downregulating the immune system would be beneficial. Two conditions, prevention of tissue rejection after allogeneic transplantation and tissue damage after autoimmunity, were chosen to prove the principles proposed. For these experiments, the entire Ad E3 cassette was introduced as a transgene controlled by the rat insulin promoter. Islets were used as targets because they are easy to isolate and have readily measured functional properties. In addition, success with these experiments might benefit a large number of patients with type I diabetes. Transplanted donor islets containing the H-2 bxd class I major histocompatibility complex (MHC) and expressing the Ad E3 transgenes demonstrated long term acceptance in allogeneic H-2 d recipients (Efrat et al., 1995) . The studies have been extended to islet transplantation from BALB H-2 k congenic donors to H-2 d recipients with similar effects (Efrat and Horwitz, personal observation); however, some combinations such as H-2 d donors into H-2 b recipients were rejected even in the presence of Ad E3 expression in donor ␤ cells. The explanation for the selectivity of successful transplantation is not completely understood, although it has been known for a long time from the work of others that the Ad2 E3-gp19K protein interacts preferentially with H-2D b and K d , and neither of the H-2 k Class I alleles binds well to the viral protein (Wold et al., 1999) . However, more recent data showing that the gp19K protein inhibits tapasin, in a process that does not depend on MHC haplotypes, may explain the success with H-2 k as donor transplants and the more general inhibition of transplant rejection.
Prevention of Diabetes in Two Mouse Models
The studies incorporating Ad E3 genes targeted for expression in ␤ cells were extended to well-established models of autoimmune diabetes. The original transgenic founders carrying E3 genes were mated with animals that readily develop type I autoimmune diabetes.
Lymphocytic Choriomeningitis Viral Proteins as Transgenic Targets for the Induction of Islet Destruction
One of the models was created in the Oldstone laboratory by also using the transgenic technique in which either of two lymphocytic choriomeningitis virus (LCMV) proteins (NP or GP) was expressed under the control of the rat insulin promoter for targeted expression in pancreatic ␤ cells (Oldstone et al., 1991) . These LCMV transgenic animals remain euglycemic until infected with LCMV, whereupon they develop a full immune response to the virus and its proteins. This antiviral response targets the LCMV protein expressed at very low levels on the surface of ␤ cells and destroys them in an immune response that requires both CD4 and CD8 cells when the NP is the target, but only CD8 cells when GP is targeted (von Herrath et al., 1997) . The presence of RIP-E3 completely prevented the onset of diabetes when LCMV-NP or -GP were expressed in the same islets. All of these animals had been previously backcrossed with H-2 b animals to eliminate any differences of MHC in the interpretation of these experiments. It appears that splenocytes even in animals carrying the Ad E3 genes were normally primed to recognize LCMV targets but they were prevented from targeting the islets in vivo in the presence of the Ad E3 transgene.
NOD Mice
The second model of diabetes in which the Ad E3 transgenes were tested for effects was the nonobese diabetic mouse (NOD). The same Ad E3 founder used for previous experiments was extensively backcrossed to NOD mice for greater than eight generations, and the 15 chromosomal regions recognized as essential for the induction of diabetes in NOD had been reconstituted as measured by microsatellite analysis in the NOD-E3 animals. Preliminary results indicate that expression of Ad E3 transgenes in pancreatic islets does protect NOD mice from diabetes, and the mechanisms responsible are currently being evaluated (Efrat et al., submitted) .
FUTURE DIRECTIONS
The proof of principle that Ad E3 genes and proteins can be used to prevent diabetes and facilitate allogeneic transplantation has been achieved. However, the system needs to be optimized. Thus far, we have been able to either prevent allogeneic transplant rejection or autoimmune destruction of islets but not been able to prevent both of these immune reactions simultaneously. For these techniques to be used to create a human islet cell line that could be used to treat type I diabetes, both parts of this immune reaction must be controlled. The attraction of this way of approaching the therapy of diabetes is that success in using such an islet line would not require systemic immunosuppression with the attendant difficulties of opportunistic infections and increased susceptibility to malignancies. Progress in the creation of human cell lines secreting appropriate amounts of insulin in response to glucose is being made. In addition, the introduction of E3 genes even into primary human islets can be achieved using Ad vectors (Leibowitz et al., 1999) . By understanding which E3 genes are responsible for the beneficial effects in vivo, it may be possible to optimize the expression of a more limited number of Ad E3 genes than in the current protocols. Such experiments on selected deletions of individual E3 proteins are underway in both the NOD and LCMV murine models. We also have postulated that removal of the only death protein (ADP) in this region will promote the beneficial effects of E3 on decreasing the immune response to target cells expressing these genes. Since there are more than 50 human adenoviruses, it is also possible that serotypes other than group C (Ad types 2 and 5) used in these experiments may have E3 regions that will be more optimal for immune regulation.
The use of FIP-1 and 14.7K to understand the function of dynein as a microtubule motor during adenovirus infection will be pursed. The potential for altering huntingtin-induced apoptosis with FIP-2 and 14.7K will be studied in cultured cells derived from selected regions of the central nervous system. Wild-type huntingtin has been shown to be essential for normal development and prevention of apoptosis (Rigamonti et al., 2000) , but mutant huntingtin protein may be amenable to functional correction with the combination of FIP-2 and 14.7K. The understanding of the interaction of FIP-3‫گ‬NEMO‫گ‬IKK␥ with other proteins on the NF-B pathway and the selective inhibition of these interactions with peptides or small molecules may be useful for the control of inflammation under a variety of conditions including the autoimmunity of diabetes, rheumatoid arthritis, and systemic lupus erythematosus. For a more complete understanding of the mechanism of action of the Ad E3 proteins, studies similar to those which produced 14.7K-interacting proteins are also underway to isolate the cell proteins that bind to the 10.4K/14.5K (RID) viral proteins.
